- In Vivo Originals
- Featured Topics
Growth
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
-
Analysis
BioBytes: AI-Related Deals In Q1 2024
By David WildBioBytes presents an overview of AI-related deals in Q1 2024. This is the first in a recurring series of quarterly deal updates.
-
Analysis
Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking
By David WildRecent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.
-
Interviews
With A Transformational Year Underway, Insmed Ramps Up
By David WildWith a reliable source of revenue in Arikayce and two key pulmonary late-stage trials reading out, Insmed aims to keep its commercial momentum going.
-
Analysis
Building Out A Blockbuster Franchise: AstraZeneca’s Growth Plans For US Lung Cancer Therapy
By Jo ShorthouseArun Krishna reveals portfolio plans for best-selling therapy Tagrisso, and its other activities to prevent, screen and diagnose lung cancer faster.
-
Analysis
Sofinnova And J&J Offer Tips For Startups Seeking Financial Backing
By David WildLast year saw a drop in series A rounds. To increase the chances of fundraising success, new companies should engage earlier and align with potential financial backers.
-
Opinion
Key Considerations When Acquiring A Cell And Gene Biotech
Stakeholders looking to gain deeper insights into potential cell and gene therapy candidates and optimize R&D strategies can employ several strategies to inform portfolio management decisions.
-
Analysis
Alys Is An Asset Play Wanting Big Pharma Attention
Leaders of a new dermatology-focused biotech, which has launched with 14 development programs in its pipeline, explain the rationale behind the company creation and the ideal exit scenario.
-
Analysis
Genmab's Growth Strategy: Embracing A ‘Super Rational, Data-Driven' Mindset
By David WildThe “Genmab sauce” will be crucial as the Danish biotech loads up on late-stage assets, grows its capabilities and expands into immunology and inflammation.
-
Analysis
Medtech’s Leading Revenue Earners In 2023: Johnson & Johnson Tops $30bn
By Ashley YeoAbbott’s weaker rapid diagnostic sales see the erstwhile industry leader slip down the global 2023 medtech rankings, while Johnson & Johnson passes it on the way up on the back of strong external and internal growth.
-
Analysis
Advice From Investors On Early-Stage Financing
By David WildStartup financing may be hard to come by, but now is not the time to ask for less cash.
-
Analysis
The ‘Biggest’ Dealmakers Of 2023 Were Not The Busiest
By Joseph HaasEli Lilly, striving to outpace Novo Nordisk, dominated the dealmaking scene in 2023 by executing six acquisitions. Although Pfizer, BMS and AbbVie sealed the largest M&A deals of the year, they did not lead in terms of volume.
-
Analysis
Private Equity And VC Fund Data: What Do The Numbers Show?
By Edwin ElmhirstIn Vivo examines trends in the venture capital and private equity funding landscapes for biotech and pharma – looking at both expenditure and gathering of capital resources.
-
Analysis
The Biopharma A List: Taking The Pulse Of Newco Creation
By Amanda MicklusOn the new company creation front, using Series A financings as a proxy, start-ups have not escaped the challenging funding environment. Here we update trends in those first-time rounds for 2023.
-
Analysis
Unpartnered Assets To Watch In 2024
By Edwin ElmhirstLicensing serves as a strategic R&D avenue for major developers amid a shrinking M&A market. In Vivo has detected five high-value unpartnered assets that might be the focus of dealmaking activity in the coming months.
-
Analysis
J.P. Morgan 2024: Financial Forecast Is Sunny For Firms Poised For Pharma Deals
By Mandy JacksonDrug developers weathered a tough 2023, but the year ended with new clarity about interest rates and big pharma M&A priorities, reducing the risk of financial storms in 2024, investors and advisors said.
-
Interviews
Rentschler’s New CEO On 2024 Expectations For CDMOs
By Lucie Ellis-TaittIn Vivo caught up with Benedikt von Braunmühl at the recent BIO-Europe conference in Munich, Germany, to discuss his first six weeks as CEO at Rentschler Biopharma and the biggest trends impacting contract development and manufacturing organizations (CDMO).
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.